# Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)

> **NCT06351748** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 34238 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT06351748
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-01-02
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-03-29
- **Target enrollment:** 34238 (ACTUAL)
- **Last updated:** 2025-04-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06351748

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06351748, "Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06351748. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*